345 related articles for article (PubMed ID: 24033414)
1. MicroRNA profile before and after antiviral therapy in liver transplant recipients for hepatitis C virus cirrhosis.
Gelley F; Zadori G; Nemes B; Fassan M; Lendvai G; Sarvary E; Doros A; Gerlei Z; Nagy P; Schaff Z; Kiss A
J Gastroenterol Hepatol; 2014 Jan; 29(1):121-7. PubMed ID: 24033414
[TBL] [Abstract][Full Text] [Related]
2. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
3. The meaning of tissue and serum HCV RNA quantitation in hepatitis C recurrence after liver transplantation: a retrospective study.
Vasuri F; Morelli MC; Gruppioni E; Fiorentino M; Ercolani G; Cescon M; Pinna AD; Grigioni WF; D'Errico-Grigioni A
Dig Liver Dis; 2013 Jun; 45(6):505-9. PubMed ID: 23317815
[TBL] [Abstract][Full Text] [Related]
4. Increased miR-16 expression induced by hepatitis C virus infection promotes liver fibrosis through downregulation of hepatocyte growth factor and Smad7.
Zhu B; Wei XX; Wang TB; Zhou YC; Liu AM; Zhang GW
Arch Virol; 2015 Aug; 160(8):2043-50. PubMed ID: 26071245
[TBL] [Abstract][Full Text] [Related]
5. Influence of antiviral therapy in the long-term outcome of recurrent hepatitis C virus infection following liver transplantation.
García-Reyne A; Lumbreras C; Fernández I; Colina F; Abradelo M; Magan P; San-Juan R; Manrique A; López-Medrano F; Fuertes A; Lizasoain M; Moreno E; Aguado JM
Transpl Infect Dis; 2013 Aug; 15(4):405-15. PubMed ID: 23725370
[TBL] [Abstract][Full Text] [Related]
6. Mir-194 is a hepatocyte gate keeper hindering HCV entry through targeting CD81 receptor.
Mekky RY; El-Ekiaby NM; Hamza MT; Elemam NM; El-Sayed M; Esmat G; Abdelaziz AI
J Infect; 2015 Jan; 70(1):78-87. PubMed ID: 25218426
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-mediated interactions between host and hepatitis C virus.
Li H; Jiang JD; Peng ZG
World J Gastroenterol; 2016 Jan; 22(4):1487-96. PubMed ID: 26819516
[TBL] [Abstract][Full Text] [Related]
8. Hepatic expression of miR-122, miR-126, miR-136 and miR-181a and their correlation to histopathological and clinical characteristics of patients with hepatitis C.
Boštjančič E; Bandelj E; Luzar B; Poljak M; Glavač D
J Viral Hepat; 2015 Feb; 22(2):146-57. PubMed ID: 25065618
[TBL] [Abstract][Full Text] [Related]
9. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
[TBL] [Abstract][Full Text] [Related]
10. Recurrent hepatitis C virus infection after liver transplantation--long-term follow-up with respect to the HCV genotypes/subtypes.
Arnold JC; Töx U; Goeser T; Otto G; Müller HM; Hofmann WJ; Stremmel W; Theilmann L
Z Gastroenterol; 1997 Apr; 35(4):255-61. PubMed ID: 9163889
[TBL] [Abstract][Full Text] [Related]
11. Serum microRNA-122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy.
Köberle V; Waidmann O; Kronenberger B; Andrei A; Susser S; Füller C; Perner D; Zeuzem S; Sarrazin C; Piiper A
J Viral Hepat; 2013 Aug; 20(8):530-5. PubMed ID: 23808991
[TBL] [Abstract][Full Text] [Related]
12. miRNA expression profiles in liver grafts of HCV and HIV/HCV-infected recipients, 6 months after liver transplantation.
Bulfoni M; Pravisani R; Dalla E; Cesselli D; Hidaka M; Di Loreto C; Eguchi S; Baccarani U
J Med Virol; 2021 Aug; 93(8):4992-5000. PubMed ID: 33818800
[TBL] [Abstract][Full Text] [Related]
13. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus and liver transplantation: where do we stand?
Burra P; De Martin E; Zanetto A; Senzolo M; Russo FP; Zanus G; Fagiuoli S
Transpl Int; 2016 Feb; 29(2):135-52. PubMed ID: 26199060
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.
Bizollon T; Palazzo U; Ducerf C; Chevallier M; Elliott M; Baulieux J; Pouyet M; Trepo C
Hepatology; 1997 Aug; 26(2):500-4. PubMed ID: 9252166
[TBL] [Abstract][Full Text] [Related]
16. Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience.
Burra P; Targhetta S; Pevere S; Boninsegna S; Guido M; Canova D; Brolese A; Masier A; D'Aloiso C; Germani G; Tomat S; Fagiuoli S
Transplant Proc; 2006 May; 38(4):1127-30. PubMed ID: 16757285
[TBL] [Abstract][Full Text] [Related]
17. Outcome and management of hepatitis C in liver transplant recipients.
Chan SE; Rosen HR
Clin Infect Dis; 2003 Sep; 37(6):807-12. PubMed ID: 12955642
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus infection decreases the expression of Toll-like receptors 3 and 7 via upregulation of miR-758.
Yang Q; Fu S; Wang J
Arch Virol; 2014 Nov; 159(11):2997-3003. PubMed ID: 25008898
[TBL] [Abstract][Full Text] [Related]
19. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.
Prieto M; Berenguer M; Rayón JM; Córdoba J; Argüello L; Carrasco D; García-Herola A; Olaso V; De Juan M; Gobernado M; Mir J; Berenguer J
Hepatology; 1999 Jan; 29(1):250-6. PubMed ID: 9862874
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppression, liver injury and post-transplant HCV recurrence.
Ciesek S; Wedemeyer H
J Viral Hepat; 2012 Jan; 19(1):1-8. PubMed ID: 22187942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
